Study of LAU-7b for the Treatment of Long COVID in Adults
Phase 2
Active, not recruiting
- Conditions
- Long COVID
- Interventions
- Drug: LAU-7b for 3 cyclesDrug: LAU-7b for 1 cycle, then placeboOther: Placebo for 3 cycles
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Laurent Pharmaceuticals Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT05999435
- Locations
- 🇨🇦
CIUSS du Saguenay-Lac-St-Jean - Hôpital Chicoutimi, Chicoutimi, Quebec, Canada
🇨🇦Montreal General Hospital, Montréal, Quebec, Canada
🇨🇦Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Quebec, Canada
Study of LAU-7b for the Treatment of COVID-19 Disease in Adults
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Laurent Pharmaceuticals Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT04417257
- Locations
- 🇺🇸
Staten Island University Hospital North, Staten Island, New York, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇺🇸MedStar Washington Hospital Center, Washington, District of Columbia, United States
Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Laurent Pharmaceuticals Inc.
- Target Recruit Count
- 166
- Registration Number
- NCT03265288
- Locations
- 🇺🇸
Division of pulmonary, critical care and sleep medicine, University of Florida, Gainesville, Florida, United States
🇦🇺Respiratory Medicine, John Hunter Hospital, New Lambton Heights, New South Wales, Australia
🇦🇺Institute of Respiratory Health, Harry Perkins Institute, Nedlands, Western Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath